November 19, 2026

To whom it may concern

Company Name: Innovacell Inc.
Representative: Representative Director and Co-CEO
Colin Lee Novick
Representative: Representative Director and Co-CEO
Jason Sieger
(Code No.: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director and CFO Yasushi Hosono
(https://innovacell.com/contact/?lang=en)

Notice Regarding Grant of a US Patent for "Methods for Obtaining Muscle Derived Cells"

Innovacell Inc. (the "Company") announces that a U.S. patent has been granded for "Methods for Obtaining Muscle Derived Cells," an application filed by its Austrian subsidiary, Innovacell GmbH.

The patent covers two investigational products in the Innovacell Group's developmental pipeline: ICEF15 for urge fecal incontinence and ICES13 for stress urinary incontinence. It is expected to enhance the commercial potential of both products in the U.S.

■ Overview of the Patent

[Patent Number]	US 12,778,987 B2
[Patent Registration Date]	November 3, 2026
[Title of the Invention]	Methods for Obtaining Muscle Derived Cells
[Patentee]	Innovacell GmbH

■ About ICEF15

ICEF15 is the most advanced product candidate in the Group's pipeline. It is being developed as a potentially curative treatment for urge fecal incontinence. The patient's own skeletal muscle-derived cells are injected into the external anal sphincter to promote muscle repair and regeneration.

Fecal incontinence is the the involuntary or uncontrolled leakage of stool from the anus. An estimated 5 million people in Japan have the condition (Source: The Japan Society of Coloproctology website).

In urge fecal incontinence, patients feel the urge to defecate but cannot hold their stool long enough to reach a toilet. It is commonly associated with impaired function of the external anal sphincter. A survey published in a specialist journal found that slightly more than half (approximately 51%) of patients with fecal incontience have urge symptoms (Toshiki Mimura et al., "Report on a Survey of the Current Status of Fecal Incontinence Care in Japan: Current Status of Diagnosis and Treatment" Journal of The Japan Society of Coloproctology 65:101–108, 2012).

■ Development Status of ICEF15

The Group is currently conducting FIDELIA, a global Phase III study of ICEF15, and aims to complete patient enrollment by the end of 2026.

■ About ICES13

ICES13 is being developed as a potentially curative treatment for stress urinary incontinence. Like ICEF15, it uses uses the patients' own cells, administered locally to promote muscle repair and regeneration.

Stress urinary incontinence is the most common form of urinary incontinence. Its main symptom is involuntary leakage of urine when abdominal pressure rises, for example during coughing or sneezing. An estimated 15.8 million women in Japan have the condition (Source: Company estimate based on Mitsui et al., "Prevalence and impact on daily life of lower urinary tract symptoms in Japan: Results of the 2023 Japan Community Health Survey (JaCS 2023)," International Journal of Urology (2024), 31, 747–754, and the Statistics Bureau of Japan's Population estimates as of October 1, 2024). The condition is thought to result mainly from weakening of or damage to the muscles of the pelvic floor muscles, including the urethral sphincter, caused by factors such as aging and childbirth.

■ Development Status of ICES13

The Group has completed a Phase IIb clinical trial of ICES13 in Europe and is preparing for the next stage of clinical development.

■ Significance of the Patent

The patent covers a method for manufacturing autologous skeletal muscle-derived cells for use in ICEF15 and ICES13. Together with a 2023 patent of the same title (US 11,617,768 B2), it strengthens protection of the manufacturing technology for both products.

■ About Innovacell Inc. (https://innovacell.com/?lang=en)

Innovacell Inc. was established in Japan in 2021 as the parent company of a cell therapy start-up company spun off from the Medical University of Innsbruck in Austria, and was listed on the Tokyo Stock Exchange Growth Market in February 2026 (Securities Code: 504A).

The Group aims to improve people's health and quality of life through the commercialization of regenerative medicine, and we are currently engaged in the research, development, and commercialization of autologous cell therapy products for the treatment of incontinence (urge fecal incontinence, passive fecal incontinence, and stress urinary incontinence). To date, the Group has completed multiple clinical trials in Europe (including late-stage Phase II trials) for two pipeline programs: ICEF15 (target indication: urge fecal incontinence) and ICES13 (target indication: stress urinary incontinence). For more details, please visit our website or our YouTube channel.

End